The Traumatic Spinal Cord Injury drugs in development market research report provides comprehensive information on the therapeutics under development for Traumatic Spinal Cord Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Traumatic Spinal Cord Injury. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Traumatic Spinal Cord Injury and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Traumatic Spinal Cord Injury by seven companies/universities/institutes. The top development phase for Traumatic Spinal Cord Injury is phase ii with three drugs in that stage. The Traumatic Spinal Cord Injury pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Traumatic Spinal Cord Injury pipeline products market are: GNT Pharma, Mitsubishi Tanabe Pharma and CSL.
The key targets in the Traumatic Spinal Cord Injury pipeline products market include Repulsive Guidance Molecule A (RGM Domain Family Member A or RGMA), Annexin A4 (35-Beta Calcimedin or Annexin 4 or Carbohydrate Binding Protein p33/p41 or Chromobindin 4 or Endonexin I or Lipocortin IV or P32.5 or PP4-X or Placental Anticoagulant Protein II or ANXA4), and Free Radical.
The key mechanisms of action in the Traumatic Spinal Cord Injury pipeline product include Repulsive Guidance Molecule A (RGM Domain Family Member A or RGMA) Inhibitor with two drugs in Phase II. The Traumatic Spinal Cord Injury pipeline products include five routes of administration with the top ROA being Intravenous and six key molecule types in the Traumatic Spinal Cord Injury pipeline products market including Cell Therapy, and Monoclonal Antibody.
Traumatic Spinal Cord Injury overview
A traumatic spinal cord injury (TSCI) is traumatic injury leading to damage of the spinal cord, resulting in temporary or permanent change to neurological function, including paralysis. It is caused by external forces like motor vehicle accidents.
For a complete picture of Traumatic Spinal Cord Injury’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
